Ingevity Q3 net sales miss estimates

Reuters
2025/11/06
Ingevity Q3 net sales miss estimates

Overview

  • Ingevity Q3 net sales from continuing operations flat yr/yr, missing analyst expectations

  • Company announces sale of Industrial Specialties and North Charleston refinery for $110 mln

Outlook

  • Ingevity revises 2025 guidance: net sales between $1.25 bln and $1.35 bln

  • Company expects 2025 adjusted EBITDA between $390 mln and $405 mln

  • Challenges in Advanced Polymer Technologies delay industrial demand recovery

Result Drivers

  • PERFORMANCE MATERIALS - Sales increased 3% driven by improved global auto production

  • ADVANCED POLYMER TECHNOLOGIES - Sales declined due to tariff impacts and increased competition in China

  • PERFORMANCE CHEMICALS - Record North America pavement sales contributed to segment growth

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Miss

$333.10 mln

$360.43 mln (3 Analysts)

Q3 EPS

$1.18

Q3 Net Income

$43.50 mln

Q3 Gross Profit

$133.90 mln

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the diversified chemicals peer group is "buy"

  • Wall Street's median 12-month price target for Ingevity Corp is $69.50, about 24.3% above its November 4 closing price of $52.58

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release: ID:nBw3mLZHma

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

应版权方要求,你需要登录查看该内容

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10